From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?

Cardiovasc Res. 2021 Sep 28;117(11):e138-e140. doi: 10.1093/cvr/cvab231.

Author

Paul M Ridker¹

Affiliation

¹ Department of Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Avenue, Boston, MA 02215, USA.

No abstract available

Keywords: Atherosclerosis; C-reactive protein; Coronary artery disease; Cytokines; Inflammation; Interleukin-6.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Inflammatory Agents / adverse effects
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Atherosclerosis / drug therapy*
Atherosclerosis / immunology
Atherosclerosis / metabolism
Cardiovascular Diseases / immunology
Cardiovascular Diseases / metabolism
Cardiovascular Diseases / prevention & control*
Heart Disease Risk Factors
Humans
Inflammation / drug therapy*
Inflammation / immunology
Inflammation / metabolism
Interleukin-6 / antagonists & inhibitors*
Interleukin-6 / immunology
Interleukin-6 / metabolism
Randomized Controlled Trials as Topic
Risk Assessment
Signal Transduction
Treatment Outcome

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized
IL6 protein, human
Interleukin-6
ziltivekimab